Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T23:29:46.038Z Has data issue: false hasContentIssue false
  • English
  • Français

Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine

Published online by Cambridge University Press:  19 July 2007

H C K Lam ,
M C F Tong  and
C A Van Hasselt
H C K Lam*
Affiliation:
Division of Otorhinolaryngology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong
M C F Tong
Affiliation:
Division of Otorhinolaryngology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong
C A Van Hasselt
Affiliation:
Division of Otorhinolaryngology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong
*
Address for correspondence: Dr Henry Chuen Kwong Lam, Division of Otorhinolaryngology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong. Fax: (852) 26466312 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To evaluate the outcome and the change in quality of life of patients with chronic rhinitis after treatment with desloratadine.

Study design:

A prospective, open-label, non-blinded, non-randomised study of patients in a secondary and tertiary ENT referral centre.

Methods:

Chinese patients with chronic rhinitis were recruited. The patients were assessed by a questionnaire that included rhinitis symptoms score and SF-36 health survey components. Endoscopic assessment was performed with a rigid nasoendoscope and scored according to the modified endoscopic appearance score of Lund and Kennedy. A 12-week course of desloratadine 5 mg daily was prescribed. Patients were re-evaluated after treatment. A total of 47 subjects completed the study.

Results:

There were significant reductions in median rhinitis symptoms score, from six to five (p < 0.001), and in median endoscopic appearance score, from five to three (p < 0.001). Patients' general health perception was also improved after treatment (p == 0.022).

Conclusion:

Desloratadine may be an effective treatment which provides symptomatic relief and improves the quality of life in patients with chronic rhinitis.

Keywords

Perennial Allergic RhinitisAntihistaminesDesloratadine
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 121 , Issue 12 , December 2007 , pp. 1151 - 1155
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Naclerio, R, Solomon, W. Rhinitis and inhalant allergens. JAMA 1997;278:1842–8CrossRefGoogle ScholarPubMed
2 Berger, WE, Schenkel, EJ, Mansfield, LE. Desloratadine Study Group. Safety and efficacy of desloratadine 5mg in asthma patients with seasonal rhinitis and nasal congestion.. Ann Allergy Asthma Immunol 2002;89:485–91CrossRefGoogle Scholar
3 Bachert, C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56 (suppl 65):14–20CrossRefGoogle ScholarPubMed
4 Corren, J, Salmun, LM. Quality of life in patients with seasonal allergic rhinitis is improved with desloratadine. Allergy 2000;5:193–4Google Scholar
5 Lebel, B, Bousquet, J, Morel, A, Chanal, I, Godard, P, Michel, FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988;5:869–77CrossRefGoogle Scholar
6 Ware, JE, Snow, KK, Kosinski, M, Gandek, B. SF36 Health Survey – Manual and Intrepretation Guide. Boston: The Health Institute, 1993Google Scholar
7 Lam, CLK, Gandek, B, Ren, XS, Chan, MS. Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 health survey. J Clin Epidemiol 1998;51:1139–47CrossRefGoogle ScholarPubMed
8 Lund, VJ, Kennedy, DW. Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol (Suppl) 1995;167(suppl):17–21CrossRefGoogle ScholarPubMed
9 Genovese, A, Patella, V, De Crescenzo, G, De Paulis, A, Spadaro, G, Marone, G. Loratadine and Desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27:559–67CrossRefGoogle ScholarPubMed
10 Lippert, U, Kruger-Krasagakes, S, Moller, A, Kiessling, U, Czarnetzki, BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272–6CrossRefGoogle ScholarPubMed
11 Kleine-Tebbe, J, Josties, C, Frank, G, Stalleicken, D, Buschauer, A, Schunack, W et al. Inhibition of IgE- and non-IgE-mediated histamine release from from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allegy Clin Immunol 1994;93:494–500CrossRefGoogle ScholarPubMed
12 Vignola, AM, Crampette, L, Mondain, M, Sauvere, G, Czarlewski, W, Bosquet, J et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995;50:200–3CrossRefGoogle ScholarPubMed
13 Geha, RS, Meltzer, EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751–62CrossRefGoogle ScholarPubMed
14 Molet, S, Gosset, P, Lassalle, P, Czarlewski, W, Tonnel, AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997;27:1167–74CrossRefGoogle ScholarPubMed
15 Lam, CLK, Lauder, IJ, Lam, TP, Gandek, B. Population based norming of the Chinese (HK) version of the SF-36 health survey. Hong Kong Practitioner 1999;21:460–70Google Scholar